Use the journals feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
Daniel H Solomon, Jon T Giles, Katherine P Liao, Paul M Ridker, Pamela M Rist, Robert J Glynn, Rachel Broderick, Fengxin Lu, Meredith T Murray, Kathleen Vanni, Leah M Santacroce, Shady Abohashem, Philip M Robson, Zahi Fayad, Venkatesh Mani, Ahmed Tawakol, Joan Bathon
OBJECTIVE: Recent large-scale randomised trials demonstrate that immunomodulators reduce cardiovascular (CV) events among the general population. However, it is uncertain whether these effects apply to rheumatoid arthritis (RA) and if certain treatment strategies in RA reduce CV risk to a greater extent. METHODS: Patients with active RA despite use of methotrexate were randomly assigned to addition of a tumour necrosis factor (TNF) inhibitor (TNFi) or addition of sulfasalazine and hydroxychloroquine (triple therapy) for 24 weeks...
November 30, 2022: Annals of the Rheumatic Diseases
#2
JOURNAL ARTICLE
Nathalie Conrad, Iain B McInnes, John J V Mcmurray, Naveed Sattar
No abstract text is available yet for this article.
November 28, 2022: Annals of the Rheumatic Diseases
#3
JOURNAL ARTICLE
Naomi J Patel, Claire Cook, Kathleen Vanni, Xiaoqing Fu, Xiaosong Wang, Yumeko Kawano, Grace Qian, Buuthien Hang, Shruthi Srivatsan, Emily P Banasiak, Emily Kowalski, Katarina Bade, Yuqing Zhang, Jeffrey A Sparks, Zachary S Wallace
OBJECTIVE: Vaccination decreases the risk of severe COVID-19 but its impact on postacute sequelae of COVID-19 (PASC) is unclear among patients with systemic autoimmune rheumatic diseases (SARDs) who may have blunted vaccine immunogenicity and be vulnerable to PASC. METHODS: We prospectively enrolled patients with SARD from a large healthcare system who survived acute infection to complete surveys. The symptom-free duration and the odds of PASC (any symptom lasting ≥28 or 90 days) were evaluated using restricted mean survival time and multivariable logistic regression, respectively, among those with and without breakthrough infection (≥14 days after initial vaccine series)...
November 28, 2022: Annals of the Rheumatic Diseases
#4
JOURNAL ARTICLE
Christopher John Redmond, Moses M Kitakule, Aran Son, McKella Sylvester, Keith Sacco, Ottavia Delmonte, Francesco Licciardi, Riccardo Castagnoli, M Cecilia Poli, Yasmin Espinoza, Camila Astudillo, Sarah E Weber, Gina A Montealegre Sanchez, Karyl S Barron, Mary Magliocco, Kerry Dobbs, Yu Zhang, Helen Matthews, Cihan Oguz, Helen C Su, Luigi D Notarangelo, Pamela Frischmeyer-Guerrerio, Daniella M Schwartz
No abstract text is available yet for this article.
November 24, 2022: Annals of the Rheumatic Diseases
#5
JOURNAL ARTICLE
Fraser L Collins, Anke J Roelofs, Rebecca A Symons, Karolina Kania, Ewan Campbell, Elaina S R Collie-Duguid, Anna H K Riemen, Susan M Clark, Cosimo De Bari
OBJECTIVES: Fibroblasts in synovium include fibroblast-like synoviocytes (FLS) in the lining and Thy1 + connective-tissue fibroblasts in the sublining. We aimed to investigate their developmental origin and relationship with adult progenitors. METHODS: To discriminate between Gdf5 -lineage cells deriving from the embryonic joint interzone and other Pdgfrα -expressing fibroblasts and progenitors, adult Gdf5-Cre;Tom;Pdgfrα-H2BGFP mice were used and cartilage injury was induced to activate progenitors...
November 22, 2022: Annals of the Rheumatic Diseases
#6
REVIEW
Sytske Anne Bergstra, Alexandre Sepriano, Andreas Kerschbaumer, Désirée van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja A Stamm, Jan W Schoones, Josef S Smolen, Robert B M Landewé
This systematic literature review (SLR) regarding the efficacy, duration of use and safety of glucocorticoids (GCs), was performed to inform the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (RA). Studies on GC efficacy were identified from a separate search on the efficacy of disease-modifying antirheumatic drugs (DMARDs). A combined search was performed for the duration of use and safety of GCs in RA patients. Dose-defined and time-defined GC treatment of any dose and duration (excluding intra-articular GCs) prescribed in combination with other DMARDs were considered...
November 21, 2022: Annals of the Rheumatic Diseases
#7
JOURNAL ARTICLE
Cecilie Henkel, Unnur Styrkársdóttir, Gudmar Thorleifsson, Lilja Stefánsdóttir, Gyda Björnsdóttir, Karina Banasik, Søren Brunak, Christian Erikstrup, Khoa Manh Dinh, Thomas Folkmann Hansen, Kaspar René Nielsen, Mie Topholm Bruun, Joseph Dowsett, Thorsten Brodersen, Thorgeir E Thorgeirsson, Kirill Gromov, Mikael Ploug Boesen, Henrik Ullum, Sisse Rye Ostrowski, Ole Birger Pedersen, Kári Stefánsson, Anders Troelsen
OBJECTIVES: Osteoarthritis is a common and severe, multifactorial disease with a well-established genetic component. However, little is known about how genetics affect disease progression, and thereby the need for joint placement. Therefore, we aimed to investigate whether the genetic associations of knee and hip osteoarthritis differ between patients treated with joint replacement and patients without joint replacement. METHODS: We included knee and hip osteoarthritis cases along with healthy controls, altogether counting >700 000 individuals...
November 14, 2022: Annals of the Rheumatic Diseases
#8
JOURNAL ARTICLE
Linda van der Weele, Tom Niessink, Mario Maas, Peter Don Griot, Matthijs Janssen, Cees Otto, Tim L Jansen, Sander W Tas, Niek de Vries
No abstract text is available yet for this article.
November 14, 2022: Annals of the Rheumatic Diseases
#9
REVIEW
Alexandre Sepriano, Andreas Kerschbaumer, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher J Edwards, Patrick Verschueren, Savia de Souza, Janet Pope, Tsutomu Takeuchi, Kimme Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja Stamm, Jan W Schoones, Robert B M Landewé
OBJECTIVES: To perform a systematic literature review (SLR) concerning the safety of synthetic(s) and biological (b) disease-modifying antirheumatic drugs (DMARDs) to inform the 2022 update of the EULAR recommendations for the management of rheumatoid arthritis (RA). METHODS: SLR of observational studies comparing safety outcomes of any DMARD with another intervention in RA. A comparator group was required for inclusion. For treatments yet without, or limited, registry data, randomised controlled trials (RCTs) were used...
November 14, 2022: Annals of the Rheumatic Diseases
#10
JOURNAL ARTICLE
Andreas Kerschbaumer, Alexandre Sepriano, Sytske Anne Bergstra, Josef S Smolen, Désirée van der Heijde, Roberto Caporali, Christopher John Edwards, Patrick Verschueren, Savia de Souza, Janet E Pope, Tsutomu Takeuchi, Kimme L Hyrich, Kevin L Winthrop, Daniel Aletaha, Tanja A Stamm, Jan W Schoones, Robert B M Landewé
OBJECTIVES: To update the evidence on efficacy of DMARDs (disease-modifying antirheumatic drugs) and inform the taskforce of the 2022 update of the European Alliance of Associations for Rheumatology (EULAR) recommendations for management of rheumatoid arthritis (RA). METHODS: This systematic literature review (SLR) investigated the efficacy of conventional synthetic (cs), biological (b), biosimilar and targeted synthetic (ts)DMARDs in patients with RA. Medline, EMBASE, Cochrane CENTRAL and Web of Science were used to identify all relevant articles published since the previous update in 2019 to 14 January 2022...
November 11, 2022: Annals of the Rheumatic Diseases
#11
JOURNAL ARTICLE
Alvise Berti, Fabiola Atzeni, Lorenzo Dagna, Stefano Del Giacco, Giacomo Emmi, Carlo Salvarani, Augusto Vaglio
Only a minority of patients with eosinophilic granulomatosis with polyangiitis (EGPA) can be weaned-off glucocorticoids (GC) using conventional treatment strategies. The development of biological agents specifically inhibiting the IL-5 pathway provided the opportunity to treat EGPA by targeting one of the crucial regulators of eosinophils, reducing the GC dose required to control the disease.The anti-IL-5 antibody mepolizumab at the dose of 300 mg/4 weeks has proven to be safe and effective in EGPA. While relapsing patients-who often experience recurrent respiratory manifestations-benefit from this treatment, data are not enough to support its use combined with GC alone in remission induction of severe active forms, or in remission maintenance without conventional immunosuppressants in patients with vasculitic manifestations...
November 10, 2022: Annals of the Rheumatic Diseases
#12
JOURNAL ARTICLE
Josef S Smolen, Robert B M Landewé, Sytske Anne Bergstra, Andreas Kerschbaumer, Alexandre Sepriano, Daniel Aletaha, Roberto Caporali, Christopher John Edwards, Kimme L Hyrich, Janet E Pope, Savia de Souza, Tanja A Stamm, Tsutomu Takeuchi, Patrick Verschueren, Kevin L Winthrop, Alejandro Balsa, Joan M Bathon, Maya H Buch, Gerd R Burmester, Frank Buttgereit, Mario Humberto Cardiel, Katerina Chatzidionysiou, Catalin Codreanu, Maurizio Cutolo, Alfons A den Broeder, Khadija El Aoufy, Axel Finckh, João Eurico Fonseca, Jacques-Eric Gottenberg, Espen A Haavardsholm, Annamaria Iagnocco, Kim Lauper, Zhanguo Li, Iain B McInnes, Eduardo F Mysler, Peter Nash, Gyula Poor, Gorica G Ristic, Felice Rivellese, Andrea Rubbert-Roth, Hendrik Schulze-Koops, Nikolay Stoilov, Anja Strangfeld, Annette van der Helm-van Mil, Elsa van Duuren, Theodora P M Vliet Vlieland, René Westhovens, Désirée van der Heijde
OBJECTIVES: To provide an update of the EULAR rheumatoid arthritis (RA) management recommendations addressing the most recent developments in the field. METHODS: An international task force was formed and solicited three systematic literature research activities on safety and efficacy of disease-modifying antirheumatic drugs (DMARDs) and glucocorticoids (GCs). The new evidence was discussed in light of the last update from 2019. A predefined voting process was applied to each overarching principle and recommendation...
November 10, 2022: Annals of the Rheumatic Diseases
#13
JOURNAL ARTICLE
Cristina Ponte, Peter C Grayson, Joanna C Robson, Ravi Suppiah, Katherine Bates Gribbons, Andrew Judge, Anthea Craven, Sara Khalid, Andrew Hutchings, Richard A Watts, Peter A Merkel, Raashid A Luqmani
OBJECTIVE: To develop and validate updated classification criteria for giant cell arteritis (GCA). METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six phases: (1) identification of candidate items, (2) prospective collection of candidate items present at the time of diagnosis, (3) expert panel review of cases, (4) data-driven reduction of candidate items, (5) derivation of a points-based risk classification score in a development data set and (6) validation in an independent data set...
November 9, 2022: Annals of the Rheumatic Diseases
#14
JOURNAL ARTICLE
Peter C Grayson, Cristina Ponte, Ravi Suppiah, Joanna C Robson, Katherine Bates Gribbons, Andrew Judge, Anthea Craven, Sara Khalid, Andrew Hutchings, Debashish Danda, Raashid A Luqmani, Richard A Watts, Peter A Merkel
OBJECTIVE: To develop and validate new classification criteria for Takayasu arteritis (TAK). METHODS: Patients with vasculitis or comparator diseases were recruited into an international cohort. The study proceeded in six phases: (1) identification of candidate criteria items, (2) collection of candidate items present at diagnosis, (3) expert panel review of cases, (4) data-driven reduction of candidate items, (5) derivation of a points-based classification score in a development data set and (6) validation in an independent data set...
November 9, 2022: Annals of the Rheumatic Diseases
#15
JOURNAL ARTICLE
George E Fragoulis, Elena Nikiphorou, Mrinalini Dey, Sizheng Steven Zhao, Delphine Sophie Courvoisier, Laurent Arnaud, Fabiola Atzeni, Georg Mn Behrens, Johannes Wj Bijlsma, Peter Böhm, Costas A Constantinou, Silvia Garcia-Diaz, Meliha Crnkic Kapetanovic, Kim Lauper, Mariana Luís, Jacques Morel, György Nagy, Eva Poleverino, Jef van Rompay, Marco Sebastiani, Anja Strangfeld, Annette de Thurah, James Galloway, Kimme L Hyrich
OBJECTIVES: To develop EULAR recommendations for screening and prophylaxis of chronic and opportunistic infections in patients with autoimmune inflammatory rheumatic diseases (AIIRD). METHODS: An international Task Force (TF) (22 members/15 countries) formulated recommendations, supported by systematic literature review findings. Level of evidence and grade of recommendation were assigned for each recommendation. Level of agreement was provided anonymously by each TF member...
November 3, 2022: Annals of the Rheumatic Diseases
#16
JOURNAL ARTICLE
Paul Studenic, Daniel Aletaha, Maarten de Wit, Tanja A Stamm, Farideh Alasti, Diane Lacaille, Josef S Smolen, David T Felson
OBJECTIVE: In 2011, the American College of Rheumatology (ACR) and EULAR endorsed provisional criteria for remission in rheumatoid arthritis (RA), both Boolean-based and index-based. Based on recent studies indicating that a higher threshold for the patient global assessment (PtGA) may improve agreement between the two sets of criteria, our goals were to externally validate a revision of the Boolean remission criteria using a higher PtGA threshold and to validate the provisionally endorsed index-based criteria...
October 24, 2022: Annals of the Rheumatic Diseases
#17
JOURNAL ARTICLE
Sofia Ramiro, Elena Nikiphorou, Alexandre Sepriano, Augusta Ortolan, Casper Webers, Xenofon Baraliakos, Robert B M Landewé, Filip E Van den Bosch, Boryana Boteva, Ann Bremander, Philippe Carron, Adrian Ciurea, Floris A van Gaalen, Pál Géher, Lianne Gensler, Josef Hermann, Manouk de Hooge, Marketa Husakova, Uta Kiltz, Clementina López-Medina, Pedro M Machado, Helena Marzo-Ortega, Anna Molto, Victoria Navarro-Compán, Michael J Nissen, Fernando M Pimentel-Santos, Denis Poddubnyy, Fabian Proft, Martin Rudwaleit, Mark Telkman, Sizheng Steven Zhao, Nelly Ziade, Désirée van der Heijde
OBJECTIVES: To update the Assessment of SpondyloArthritis international Society (ASAS)-EULAR recommendations for the management of axial spondyloarthritis (axSpA). METHODS: Following the EULAR Standardised Operating Procedures, two systematic literature reviews were conducted on non-pharmacological and pharmacological treatment of axSpA. In a task force meeting, the evidence was presented, discussed, and overarching principles and recommendations were updated, followed by voting...
October 21, 2022: Annals of the Rheumatic Diseases
#18
REVIEW
Casper Webers, Augusta Ortolan, Alexandre Sepriano, Louise Falzon, Xenofon Baraliakos, Robert B M Landewé, Sofia Ramiro, Désirée van der Heijde, Elena Nikiphorou
OBJECTIVE: To update the evidence on efficacy and safety of biological disease-modifying antirheumatic drugs (bDMARDs) in patients with axial spondyloarthritis (axSpA) to inform the 2022 update of the Assessment of SpondyloArthritis international Society/European Alliance of Associations for Rheumatology (ASAS-EULAR) recommendations for the management of axSpA. METHODS: Systematic literature review (2016-2021) on efficacy and safety of bDMARDs in axSpA (radiographic axSpA (r-axSpA)/non-radiographic axSpA (nr-axSpA))...
October 21, 2022: Annals of the Rheumatic Diseases
#19
JOURNAL ARTICLE
Zihan Zheng, Ling Chang, Jie Mu, Qingshan Ni, Zhong Bing, Qing-Hua Zou, Ying Wan, Yuzhang Wu, Jingyi Li, Liyun Zou
No abstract text is available yet for this article.
October 19, 2022: Annals of the Rheumatic Diseases
#20
JOURNAL ARTICLE
Xiaozhao Wang, Qin Wu, Ru Zhang, Zhang Fan, Wenyue Li, Renwei Mao, Zihao Du, Xudong Yao, Yuanzhu Ma, Yiyang Yan, Wei Sun, Hongwei Wu, Wei Wei, Yejun Hu, Yi Hong, Huan Hu, Yi Wen Koh, Wangping Duan, Xiao Chen, Hongwei Ouyang
OBJECTIVES: This study investigated the stage-specific and location-specific deposition and characteristics of minerals in human osteoarthritis (OA) cartilages via multiple nano-analytical technologies. METHODS: Normal and OA cartilages were serially sectioned for micro-CT, scanning electron microscopy with energy dispersive X-ray spectroscopy, micro-Raman spectroscopy, focused ion beam scanning electron microscopy, high-resolution electron energy loss spectrometry with transmission electron microscopy, nanoindentation and atomic force microscopy to analyse the structural, compositional and mechanical properties of cartilage in OA progression...
October 19, 2022: Annals of the Rheumatic Diseases
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
